These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 19638271)
1. Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program. Shahzad A; Köhler G Vaccine; 2009 Aug; 27(39):5293-4. PubMed ID: 19638271 [TBL] [Abstract][Full Text] [Related]
2. A developing country perspective on vaccine-associated paralytic poliomyelitis. John TJ Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301 [TBL] [Abstract][Full Text] [Related]
3. Cost analysis of post-polio certification immunization policies. Sangrujee N; Cáceres VM; Cochi SL Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295 [TBL] [Abstract][Full Text] [Related]
4. World wide experience with inactivated poliovirus vaccine. Bonnet MC; Dutta A Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology of poliomyelitis--options and update. Dutta A Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232 [TBL] [Abstract][Full Text] [Related]
6. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV? Khan MM Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460 [TBL] [Abstract][Full Text] [Related]
7. [Universal use of inactivated poliovirus vaccine--the needs and challenges]. Shimizu H; Takeda N Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495 [TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of alternative polio immunization policies in South Africa. Griffiths UK; Botham L; Schoub BD Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096 [TBL] [Abstract][Full Text] [Related]
9. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Heinsbroek E; Ruitenberg EJ Vaccine; 2010 May; 28(22):3778-83. PubMed ID: 20362626 [TBL] [Abstract][Full Text] [Related]
10. Polio eradication: the OPV paradox. Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339 [TBL] [Abstract][Full Text] [Related]
11. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Nelson KS; Janssen JM; Troy SB; Maldonado Y Vaccine; 2012 Jan; 30(2):121-5. PubMed ID: 22100886 [TBL] [Abstract][Full Text] [Related]
15. [The perspective of global eradication of poliomyelitis]. Knolle H; Egli A; Candrian U Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784 [TBL] [Abstract][Full Text] [Related]
16. Strengths and weaknesses of current polio vaccines--a view from industry. André FE Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338 [TBL] [Abstract][Full Text] [Related]
17. Possible global strategies for stopping polio vaccination and how they could be harmonized. Cochi SL; Sutter RW; Aylward RB Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323 [TBL] [Abstract][Full Text] [Related]
18. The final stages of the global eradication of polio. John TJ N Engl J Med; 2000 Sep; 343(11):806-7. PubMed ID: 10984572 [No Abstract] [Full Text] [Related]
19. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Thompson KM; Duintjer Tebbens RJ Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581 [TBL] [Abstract][Full Text] [Related]
20. The bumpy road to polio eradication. Modlin JF N Engl J Med; 2010 Jun; 362(25):2346-9. PubMed ID: 20573922 [No Abstract] [Full Text] [Related] [Next] [New Search]